Rheumatoid Arthritis Therapeutics Market Size - Industry Analysis Report, Regional Outlook, Application Potential, Price Trends, Competitive Market Share & Forecast, 2025 - 2034
Report ID: GMI4247
Download Free PDF
Authors:
Monali Tayade,
Rheumatoid Arthritis Therapeutics Market Size
The global rheumatoid arthritis therapeutics market generated considerable revenue in 2024 and is projected to grow at a decent CAGR during 2025-2034, driven by the rising incidence of rheumatoid arthritis, the increasing number of biologics, and the potential increase in an older population with more susceptibility to autoimmune diseases.
As per NIH. org by 2050, nearly 31.7 million individuals worldwide would be living with rheumatoid arthritis, and about 68.7% of those would be women. RA, a chronic inflammatory disease that can lead to the inability to perform daily activities, has become a significant concern internationally for older adults and women, and the chronicity of the disorder affects quality of life, making it a major issue.
There is increased discussion regarding the load of autoimmune diseases, with a high percentage attributable to RA. In 2024, the drug landscape of RA will emerge with newer therapeutic classes, including Janus kinase (JAK) inhibitors and interleukin-6 (IL-6) blockers, which are critical new advancements to treatment for patients with RA, along with the conventional disease-modifying antirheumatic drugs (DMARDs) and tumor necrosis factor inhibitors (TNFs).
Lifestyle factors that are related to RA (such as smoking, obesity, and sedentary lifestyle) also contribute to higher patient numbers with the disease. Additionally, increasing awareness of the importance of early diagnosis and early treatment is improving patient access to therapeutics. In the context of the points, newly approved targeted biologics and biosimilars have also contributed to market growth, as they allow for more therapeutic options to be provided at lower prices.
However, even with the availability of biologic therapies and a large supply of potential patients and healthcare demand, the price of these therapies, in combination with chronic disease RA that necessitates lifelong treatment, is costly for patients and healthcare systems alike. Equitable market access is challenged with limited accessibility in low- and middle-income areas, delayed diagnosis due lack of awareness regarding RA, among other barriers.
Rheumatoid Arthritis Therapeutics Market Trends
Several noteworthy trends are expected to shape the future of the rheumatoid arthritis therapeutics market. Among the plethora of trends, the rise of personalized and precision medicine is prominently emerging, as treatment regimens evolve, leveraging genetic and biomarker data, whereby patient management is better tailored and optimized, improving patient outcomes at the same time while minimizing adverse drug effects.
Similarly, the rise of JAK inhibitors and oral small-molecule drugs designed to replace conventional biologics using a convenient route of administration is growing rapidly for the RA (and wider rheumatology) market. As more patents for major biologics expire, biosimilars are also helping to increase competition at a regional level, especially in price-sensitive areas, enhancing access to previously unaffordable biologics through increased market competition. Digital applications, mobile health, seen alongside a growing trend to include remote monitoring devices, are moving into the RA care space that will allow for better and more real-time tracking of symptoms, medication schedules, and flare-ups.
Rheumatoid Arthritis Therapeutics Market Analysis
The pharmaceuticals segment in the rheumatoid arthritis therapeutics market held sizeable growth in 2024, due to their efficacy in terms of clinical outcomes related to slowing disease progression, managing inflammation, and maintaining function. It includes a multitude of approaches to therapy, including conventional DMARDs and biologics (TNF inhibitors, IL-6 inhibitors, B-cell therapy, T-cell co-stimulation modulators, etc.), along with new classes such as Janus kinase (JAK) inhibitors.
Adalimumab and etanercept continue to be among the top-performing therapies in this segment. Biosimilars have entered the market and continue to grow as costs become prohibitive for some patients in some cost-sensitive markets. The JAK inhibitors segment is growing quickly because of oral administration and the positive clinical data in patients previously intolerant or nonresponsive to biologics. The current research and development in pharmaceuticals is ever-innovative, while clinical trials are expanding the therapeutic toolbox. There are even emerging pipeline products that show promise for patients with refractory or difficult-to-treat RA.
The online pharmacy segment in the rheumatoid arthritis therapeutics market witnessed robust growth in 2024, driven by the trends towards digital health and remote access to medications. The online pharmacy segment offers a variety of perceived benefits that include home delivery, better pricing, and an element of privacy for patients, who may prefer it to traditional pharmacies, especially for subscription refills. As the mobility challenges of RA can preclude, the conveniences offered by online pharmacies are attractive to patients.
Online pharmacies provide physicians and patients with convenience and access to their medications promptly. Online pharmacies utilize integrated AI tools to provide automated reminders, virtual consultations with pharmacists, and personalized medication management services. The continued acceptance of e-commerce as a legitimate platform for healthcare, increasing digital literacy, and the rise of reliable e-pharmacy platforms are helping to spur the growth of this segment.
Europe rheumatoid arthritis therapeutics market held sustainable growth in 2024 with a firm health care infrastructure, access to biologics, and supportive reimbursement policies. The European Medicines Agency (EMA) will continue to be a pace-setter in conducting studies to support accelerated approval for innovative therapies, along with guaranteeing patient safety. Over the past several years, there has been a positive increase in the market uptake of biologics biosimilars across European countries, i.e., Europe, the health systems have needed to find ways to keep costs to their citizens stable while obtaining more access to care.
An example of this has been as a result of biosimilars in clinical use, particularly for infliximab and adalimumab have established increased access to treatment affordability without compromising care. As with the previous reasons to improve health outcomes with RA, the national health systems of Europe are investing in early screening and collaborative care models to reflect RA management.
Rheumatoid Arthritis Therapeutics Market Share
Major companies in the rheumatoid arthritis therapeutics industry include:
To increase brand visibility, companies operating in the rheumatoid arthritis (RA) therapeutics space have used various legal strategies (including considerable investment in R&D in new biologic medicines, JAK inhibitors, and personalized therapies). Companies are also forming novel partnerships, collaboratives, and consortia with biotech companies, universities, and research centers to gain access to new drug platforms and move toward clinical development.
Major pharmaceutical players also focus on securing regulatory approval in priority markets for commercialization to get ahead of other products. If firms can delay the release of biosimilars and strategic licensing by advancing competitive pricing and shared platform models, they can garner cost-sensitive markets. Companies are increasingly stealing market share by marketing patient education programs, as well as selling low or no-cost reimbursement or access initiatives that seek to enhance treatment affordability.
Rheumatoid Arthritis Therapeutics Market News
Research methodology, data sources & validation process
This report draws on a structured research process built around direct industry conversations, proprietary modelling, and rigorous cross-validation and not just desk research.
Our 6-step research process
1. Research design & analyst oversight
At GMI, our research methodology is built on a foundation of human expertise, rigorous validation, and complete transparency. Every insight, trend analysis, and forecast in our reports is developed by experienced analysts who understand the nuances of your market.
Our approach integrates extensive primary research through direct engagement with industry participants and experts, complemented by comprehensive secondary research from verified global sources. We apply quantified impact analysis to deliver dependable forecasts, while maintaining complete traceability from original data sources to final insights.
2. Primary research
Primary research forms the backbone of our methodology, contributing nearly 80% to overall insights. It involves direct engagement with industry participants to ensure accuracy and depth in analysis. Our structured interview program covers regional and global markets, with inputs from C-suite executives, directors, and subject matter experts. These interactions provide strategic, operational, and technical perspectives, enabling well-rounded insights and reliable market forecasts.
3. Data mining & market analysis
Data mining is a key part of our research process, contributing nearly 20% to the overall methodology. It involves analysing market structure, identifying industry trends, and assessing macroeconomic factors through revenue share analysis of major players. Relevant data is collected from both paid and unpaid sources to build a reliable database. This information is then integrated to support primary research and market sizing, with validation from key stakeholders such as distributors, manufacturers, and associations.
4. Market sizing
Our market sizing is built on a bottom-up approach, starting with company revenue data gathered directly through primary interviews, alongside production volume figures from manufacturers and installation or deployment statistics. These inputs are then pieced together across regional markets to arrive at a global estimate that stays grounded in actual industry activity.
5. Forecast model & key assumptions
Every forecast includes explicit documentation of:
✓ Key growth drivers and their assumed impact
✓ Restraining factors and mitigation scenarios
✓ Regulatory assumptions and policy change risk
✓ Technology adoption curve parameter
✓ Macroeconomic assumptions (GDP growth, inflation, currency)
✓ Competitive dynamics and market entry/exit expectations
6. Validation & quality assurance
The final stages involve human validation, where domain experts manually review filtered data to identify nuances and contextual errors that automated systems might miss. This expert review adds a critical layer of quality assurance, ensuring data aligns with research objectives and domain-specific standards.
Our triple-layer validation process ensures maximum data reliability:
✓ Statistical Validation
✓ Expert Validation
✓ Market Reality Check
Trust & credibility
Verified data sources
Trade publications
Security & defense sector journals and trade press
Industry databases
Proprietary and third-party market databases
Regulatory filings
Government procurement records and policy documents
Academic research
University studies and specialist institution reports
Company reports
Annual reports, investor presentations, and filings
Expert interviews
C-suite, procurement leads, and technical specialists
GMI archive
13,000+ published studies across 30+ industry verticals
Trade data
Import/export volumes, HS codes, and customs records
Parameters studied & evaluated
Every data point in this report is validated through primary interviews, true bottom-up modelling, and rigorous cross-checks. Read about our research process →